BR112018009886A2 - composições e dispositivos de liberação transdérmica resistentes ao abuso compreendendo um agonista opioide e um derivado n-óxido de um antagonista opioide não liberado transdermicamente para o tratamento da dor - Google Patents

composições e dispositivos de liberação transdérmica resistentes ao abuso compreendendo um agonista opioide e um derivado n-óxido de um antagonista opioide não liberado transdermicamente para o tratamento da dor

Info

Publication number
BR112018009886A2
BR112018009886A2 BR112018009886A BR112018009886A BR112018009886A2 BR 112018009886 A2 BR112018009886 A2 BR 112018009886A2 BR 112018009886 A BR112018009886 A BR 112018009886A BR 112018009886 A BR112018009886 A BR 112018009886A BR 112018009886 A2 BR112018009886 A2 BR 112018009886A2
Authority
BR
Brazil
Prior art keywords
transdermally
abuse
pain
transdermal delivery
treatment
Prior art date
Application number
BR112018009886A
Other languages
English (en)
Inventor
Whitelock Steve
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of BR112018009886A2 publication Critical patent/BR112018009886A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção refere-se a um dispositivo de liberação transdérmica que compreende uma composição farmacêutica, em que a composição compreende um derivado n-óxido de um antagonista opioide, ou um sal do mesmo, e um agonista opioide ou sal do mesmo.
BR112018009886A 2015-11-19 2016-11-18 composições e dispositivos de liberação transdérmica resistentes ao abuso compreendendo um agonista opioide e um derivado n-óxido de um antagonista opioide não liberado transdermicamente para o tratamento da dor BR112018009886A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1520390.4A GB201520390D0 (en) 2015-11-19 2015-11-19 Composition
PCT/GB2016/053600 WO2017085502A1 (en) 2015-11-19 2016-11-18 Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain

Publications (1)

Publication Number Publication Date
BR112018009886A2 true BR112018009886A2 (pt) 2018-11-13

Family

ID=55133015

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018009886A BR112018009886A2 (pt) 2015-11-19 2016-11-18 composições e dispositivos de liberação transdérmica resistentes ao abuso compreendendo um agonista opioide e um derivado n-óxido de um antagonista opioide não liberado transdermicamente para o tratamento da dor

Country Status (14)

Country Link
US (1) US20180344726A1 (pt)
EP (1) EP3377048B1 (pt)
JP (1) JP2018534319A (pt)
KR (1) KR20180074797A (pt)
CN (1) CN108601747A (pt)
AU (1) AU2016355113A1 (pt)
BR (1) BR112018009886A2 (pt)
CA (1) CA3005775A1 (pt)
ES (1) ES2799516T3 (pt)
GB (1) GB201520390D0 (pt)
IL (1) IL259457A (pt)
MX (1) MX2018006157A (pt)
SG (1) SG11201803913RA (pt)
WO (1) WO2017085502A1 (pt)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722928A (en) * 1985-12-02 1988-02-02 E. I. Du Pont De Nemours And Company N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes
EP1299104B1 (en) * 2000-02-08 2009-05-13 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
GB0026137D0 (en) * 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
EA007240B1 (ru) * 2002-06-10 2006-08-25 Еуро-Селтик С. А. Системы дезактивации активного вещества в трансдермальном средстве
PT1718258E (pt) * 2004-02-23 2009-06-16 Euro Celtique Sa Dispositivo de administração transdérmica de opióides com resistência ao abuso
JP2010510326A (ja) * 2006-11-22 2010-04-02 プロジェニックス ファーマスーティカルス インコーポレーテッド ４，５−エポキシ−モルフィナニウム類似体のｎ−オキシド類
WO2009067275A1 (en) * 2007-11-21 2009-05-28 Progenics Pharmaceuticals, Inc N-oxides of 4,5-epoxy-morphinanium analogs
MX2010010512A (es) * 2008-03-26 2010-11-09 Alltranz Inc Formulaciones transdermicas de agonistas y antagonistas-agonistas de opiato que impiden el abuso.
US8829020B2 (en) * 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
WO2011123866A1 (en) * 2010-04-02 2011-10-06 Alltranz Inc. Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists

Also Published As

Publication number Publication date
EP3377048A1 (en) 2018-09-26
KR20180074797A (ko) 2018-07-03
JP2018534319A (ja) 2018-11-22
AU2016355113A1 (en) 2018-05-24
CN108601747A (zh) 2018-09-28
SG11201803913RA (en) 2018-06-28
CA3005775A1 (en) 2017-05-26
GB201520390D0 (en) 2016-01-06
US20180344726A1 (en) 2018-12-06
MX2018006157A (es) 2019-04-04
EP3377048B1 (en) 2020-04-22
IL259457A (en) 2018-07-31
ES2799516T3 (es) 2020-12-18
WO2017085502A1 (en) 2017-05-26

Similar Documents

Publication Publication Date Title
MX2018012486A (es) Composiciones para aplicacion topica de compuestos.
BR112017003546A2 (pt) amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
BR112017011972A2 (pt) derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
BR112017007072A2 (pt) compostos de triazolopiridina e métodos para o tratamento de fibrose cística
BR112016022345A2 (pt) terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40
GB2538682A (en) Nasal drug products and methods of their use
BR112016012713A2 (pt) Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento
MX2014004766A (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
EP3498279A4 (en) PHARMACEUTICAL COMPOSITION WITH AMODIAQUIN AND ANTIDIABETIC MEDICINAL PRODUCT AS AN ACTIVE SUBSTANCE FOR PREVENTING OR TREATING DIABETES
BR112016001781A2 (pt) inibidores de rorc2 e métodos de uso dos mesmos
CY1122968T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112015022846A2 (pt) uso de um composto para tratar ou prevenir um angioedema mediado pelo receptor b2 da bradicinina e formulação compreendendo o mesmo
CR20150505A (es) Derivado de dihidropiridazin-3,5-diona
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
BR112019004684A2 (pt) combinação de agonistas de fxr
CL2015002847A1 (es) Sistemas y métodos para tratar una respuesta farmacodinámica adversa inducida por opioides (divisional de la solicitud n° 0110-2015).
EP3138834A4 (en) Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient
SG11201605868XA (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
BR112017008721A2 (pt) formulação líquida injetável, composição de liberação controlada, e, métodos para entrega prolongada de buprenorfina, para formação de uma composição de liberação controlada e para tratamento ou profilaxia de um sujeito animal humano ou não humano.
BR112018002520A2 (pt) Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
BR112018007625A2 (pt) composição antibacteriana combinada e regime antibacteriano de curto prazo
CY1121773T1 (el) Χρηση του παλμιτοϋλοαιθανολαμιδιου σε συνδυασμο με οπιοειδη

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]